Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-small Cell Lung Cancer
Clinical trial register · China

Non-small Cell Lung Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 131 Beijing 124 Shanghai 86 Changsha 72 Fuzhou 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.17 Hunan Province Tumor Hospital16 AstraZeneca16 Sun Yat-sen University13 Shanghai Chest Hospital12
Site location
Guangzhou131 Beijing124 Shanghai86 Changsha72 Fuzhou59
All 110 locations
Target enrolment
to

Non-small Cell Lung Cancer trials in China

385 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
RemeGen Co., Ltd.
Phase 1/2
26
Shanghai
2027-12-01
Not yet open
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
436
Shanghai, Hangzhou
2026-12
Not yet open
Peking University People's Hospital
Not applicable
50
Beijing
2026-11-01
Not yet open
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
660
Guangzhou
2026-10-30
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
12
Wuhan
2026-10-10
Recruiting
Hansoh BioMedical R&D Company
Phase 2
76
Wuhan
2026-10-08
Recruiting
Hoffmann-La Roche
Phase 3
400
Guangzhou
2026-10-06
Not yet open
Acupuncture and Laser Acupuncture for Advanced Non-Small Cell Lung Cancer
NCT07879768Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
China Medical University, Taiwan
Not applicable
90
2026-10-01
Not yet open
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
NCT07889297Non-Small Cell Lung Cancer, Pulmonary Metastases
Shanghai Chest Hospital
Not applicable
15
Shanghai
2026-10
Not yet open
The First People's Hospital of Lianyungang
Phase 2
61
Lianyungang
2026-10
Not yet open
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
NCT07875465Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic
Bing Xia
Phase 2
120
Hangzhou
2026-10
Recruiting
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Dongguan Shi, Guangzhou, Jiangmen, Zhongshan, Guilin
2026-09-08
Not yet open
First Affiliated Hospital of Guangxi Medical University
Observational
500
Nanning
2026-09-01
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
36
Guangzhou
2026-09
Recruiting
Guangdong Association of Clinical Trials
Phase 2
32
Guangzhou, Wuhan
2026-08-28
Not yet open
Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC
NCT07698990Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Not applicable
1,200
Shanghai
2026-08-21
Not yet open
Sichuan Cancer Hospital and Research Institute
Phase 2
43
Chengdu
2026-08-20
Recruiting
AstraZeneca
Observational
100
Beijing
2026-08-13
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
90
Shanghai
2026-07-24
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
Recruiting
Akeso
Phase 1/2
265
Shanghai
2026-07-07
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 1/2
45
Nanchang
2026-07-03
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-07-01
Not yet open
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
NCT07699757Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
DrugsHSK41959·Cisplatin/Carboplatin·Sintilimab·Nab-paclitaxel
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
258
Shanghai
2026-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Guangzhou, Guilin, Nanning, Shijiazhuang, Wuhan
2026-06-18
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
15
Hangzhou
2026-06-16
Recruiting
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
NCT07623369Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
Huahui Health
Phase 1
299
Jinan
2026-06-11
Not yet open
Anhui Provincial Cancer Hospital
Phase 2
154
Hefei
2026-06-06
Recruiting
AstraZeneca
Not applicable
1,000
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou
2026-06-02
Recruiting
Shanghai Juncell Therapeutics
Phase 2
28
Shanghai
2026-06-01
Not yet open
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1
186
Shanghai
2026-06
Recruiting
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Not yet open
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
NCT07558200Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
DrugTEV-56278
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
138
Shanghai
2026-05-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
2026-05-04
Not yet open
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
DrugsEtoposide and carboplatin·Limertinib
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2026-05-01
Recruiting
IMP3-saRNA Vaccine in Advanced NSCLC
NCT07561723Non-Small Cell Lung Cancer
West China Hospital
Phase 1
9
Chengdu
2026-04-30
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
90
Jinan
2026-04-29
Recruiting
Gang Hou
Phase 1/2
105
Beijing
2026-04-24
Not yet open
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
NCT07545213Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
DrugsAnlotinib·Sacituzumab tirumotecan
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2
27
Yiwu
2026-04-20
Recruiting
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
45
Shanghai
2026-04-01
Recruiting
Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)
NCT07564557Non-small Cell Lung Cancer, Early-stage Lung Cancer, Deep-seated Lung Nodules, Solid-dominant Lung Cancer
Shanghai Chest Hospital
Not applicable
89
Shanghai
2026-04-01
Recruiting
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
NCT07589205Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 1
493
Tianjin
2026-03-31
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
30
Beijing
2026-03-30
Recruiting
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
NCT07487883Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules, PET/CT
Peking University People's Hospital
Observational
80
Beijing
2026-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Shanghai, Hangzhou
2026-03-18
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
40
Guangzhou
2026-03-11
Recruiting
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07641023Non-Small Cell Lung Cancer, Advanced/Metastatic
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
NCT07413757Non-Small Cell Lung Cancer
AstraZeneca
Observational
590
Chengdu
2026-03-02
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
45
Guangzhou, Zhengzhou, Chengdu
2026-02-26
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07467863Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
NCT07374614Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib
Peking University Shenzhen Hospital
Observational
20
Shenzhen
2026-01-31
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Taizhou
2026-01-30
By invitation
Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Phase 1
12
Wuhan
2026-01-29
Recruiting
Shanghai Henlius Biotech
Phase 2
60
Shanghai
2026-01-20
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
Electro-Acupuncture in Lung cancER : EALER Study
NCT07337096Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors
Guangzhou University of Traditional Chinese Medicine
Not applicable
424
Guangzhou, Nanjing
2026-01-15
Recruiting
Fujian Cancer Hospital
Phase 4
60
Fuzhou
2026-01-15
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
Peking Union Medical College Hospital
Not applicable
30
Beijing
2026-01-03
Not yet open
Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
NCT07347977Non-Small Cell Lung Cancer, Recurrence, Survival Analysis
DrugLidocaine
First Affiliated Hospital of Ningbo University
Not applicable
1,400
Ningbo
2026-01-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Cangzhou, Tianjin
2025-12-22
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
Recruiting
Fudan University
Not applicable
384
Shanghai
2025-12-15
Recruiting
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, Ürümqi
2025-12-10
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
NCT07239661Non-Small Cell Lung Cancer, Electroacupuncture, PD-1 Inhibitors, ECOG PS 2 Points
Kong Fanming
Not applicable
120
Tianjin
2025-11-30
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
FL-261 Imaging for Cancer Diagnosis and Staging
NCT07510321Non-Small Cell Lung Cancer, Colorectal Cancer, Head & Neck Cancer, Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
12
Wuhan
2025-11-27
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
300
Guangzhou
2025-11-24
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou
2025-11-11
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Beijing, Chongqing, Fuzhou, Jiangmen, Anyang, Luoyang, Jingzhou, Wuhan
2025-11-05
By invitation
Ming Yang
Observational
380
Beijing
2025-11-01
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
582
Guangzhou
2025-10-30
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsTam-Peli·Ivonescimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Active, closed
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
Anhui Provincial Cancer Hospital
Not applicable
12
Hefei
2025-09-20
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Not yet open
Akeso
Phase 2
60
Guangzhou
2025-09-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Not yet open
Fuzhou General Hospital
Observational
35
Fuzhou
2025-08-20
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
134
Wuhan
2025-08-20
Recruiting
Wayshine Biopharm, Inc.
Phase 2
40
Fuzhou, Wuhan, Shanghai, Tianjin
2025-08-18
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
A Study of YL202 in Patients With Advanced Solid Tumors
NCT07202364Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
DrugYL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Changsha
2025-08-04
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai
2025-07-30
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
31
Shanghai
2025-07-30
Recruiting
Cytocraft Biopharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-07-26
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
Dizal Pharmaceuticals
Phase 1/2
180
Shanghai
2025-07-16
Recruiting
Akeso
Phase 3
536
Shanghai
2025-07-08
Recruiting
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
NCT07086300Elderly Patients (>65 Years), Non-Small Cell Lung Cancer, PD-1 Inhibitors, Electroacupuncture
Kong Fanming
Not applicable
120
Tianjin
2025-07-08
Recruiting
Beijing Pearl Biotechnology Limited Liability Company
Phase 3
300
Beijing, Guangzhou
2025-07-07
Recruiting
Sichuan University
Phase 2
30
Chengdu
2025-07-04
Recruiting
Tongji Hospital
Observational
100
Wuhan
2025-07-02
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
DrugsVenetocalx·Ivonescimab
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Recruiting
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Not yet open
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
126
Chongqing
2025-06-30
Not yet open
The First Affiliated Hospital of Xiamen University
Phase 2
43
Xiamen
2025-06-30
Recruiting
Sichuan University
Phase 2
40
Chengdu
2025-06-25
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
69
Jinan
2025-06-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-06-15
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
224
Beijing
2025-06-11
Recruiting
Shanghai Henlius Biotech
Phase 2
243
Beijing
2025-06-09
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Observational
100
Hangzhou
2025-06-04
Active, closed
Shanghai Chest Hospital
Phase 2/3
97
Shanghai
2025-06-03
Recruiting
FAP-targeted PET/NIR in Lung Malignant Tumors
NCT07498933Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
Peking University People's Hospital
Observational
200
Beijing
2025-06-03
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
NCT06896422Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
DrugGlutathione
The First Affiliated Hospital of Zhengzhou University
Phase 1
80
Zhengzhou
2025-06-01
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
762
Hangzhou, Shanghai
2025-05-30
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
50
Shanghai
2025-05-23
Recruiting
China Medical University, China
Phase 2
40
Shenyang
2025-05-12
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2025-05-09
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
18
Hangzhou
2025-05-09
Not yet open
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC
NCT06966583Solid Tumor, Non Small Cell Lung Cancer
Sichuan University
Phase 1
20
Chengdu
2025-05-01
Not yet open
Hunan Province Tumor Hospital
Phase 3
94
Changsha
2025-05-01
Active, closed
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
30
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 2/3
30
Nanchang
2025-04-21
Recruiting
Shanghai JMT-Bio Inc.
Phase 3
350
Beijing
2025-04-03
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Recruiting
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
NCT06930807Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
Peking University People's Hospital
Not applicable
1,000
Beijing
2025-03-25
Active, closed
RemeGen Co., Ltd.
Phase 1
121
Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang
2025-03-13
By invitation
Qianfoshan Hospital
Observational
43
Jinan
2025-03-12
Not yet open
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial
NCT06848426Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Jiangxi Provincial People's Hopital
Not applicable
100
Nanchang
2025-03-10
Recruiting
Peking Union Medical College Hospital
Phase 1
18
Beijing
2025-03-01
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
63
Beijing
2025-03-01
Recruiting
Baohui Han
Observational
508
Shanghai
2025-03-01
Recruiting
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Shanghai Henlius Biotech
Phase 1/2
105
Hunan, Jinan, Chongqing
2025-02-25
Recruiting
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
NCT06840704Non Small Cell Lung Cancer, Small Cell Lung Cancer
Hunan Cancer Hospital
Phase 3
121
Changsha, Chenzhou, Hengyang, Yueyang
2025-02-25
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
720
Shanghai
2025-02-24
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
20
Hangzhou
2025-02-20
Recruiting
Fudan University
Phase 2
34
Shanghai
2025-02-07
Not yet open
Henan Cancer Hospital
Observational
55
Zhengzhou
2025-02-01
Recruiting
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Recruiting
Study on the Mechanism of Acquired Resistance of Entrectinib
NCT07199959ROS1 Fusion Positive, Non Small Cell Lung Cancer
DrugEntrectinib
Fudan University
Observational
38
Shanghai
2025-01-15
Recruiting
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
DrugSintilimab
Sichuan University
Phase 2
100
Chengdu, Suining
2025-01-10
Active, closed
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Ha’erbin, Hefei, Jiangmen, Kunming
2025-01-09
Recruiting
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan
2025-01-07
Not yet open
Zhongnan Hospital
Not applicable
60
Wuhan
2025-01-01
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
40
Beijing
2025-01-01
Recruiting
Kong Fanming
Phase 2/3
405
Tianjin
2025-01-01
Recruiting
Ruijin Hospital
Observational
40
Shanghai
2024-12-30
Not yet open
Peking Union Medical College Hospital
Phase 2
316
Beijing
2024-12-17
Recruiting
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
NCT06621563Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
DrugsHS-20117·Capeox·MFOLFOX6·Folfox
Hansoh BioMedical R&D Company
Phase 1
780
Tianjin
2024-12-14
Not yet open
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2024-11-30
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
498
Guangzhou
2024-11-29
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
420
Guangzhou
2024-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
6
Changsha
2024-11-13
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Folfox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Recruiting
Peng Zhang
Phase 2
60
Shanghai
2024-11-07
Recruiting
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
NCT06702826Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
DrugCadonilimab
Rongrong Zhou
Phase 2
20
Changsha
2024-11-01
Not yet open
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
350
Wuhan
2024-10-31
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Active, closed
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Not yet open
BioSyngen Pte Ltd
Not applicable
12
Shenzhen
2024-10-24
Active, closed
Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.
NCT07274761Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer
DrugSunvozertinib
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
24
Shanghai
2024-10-17
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Shanghai
2024-10-16
By invitation
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
NCT06876675Non-Small Cell Lung Cancer, Hyperlipidemia
DrugLorlatinib
Peking University Third Hospital
Observational
167
Beijing
2024-10-15
Active, closed
National Cancer Center, China
Phase 2
30
Beijing
2024-10-14
Recruiting
A Phase Ib Study of GC101 in NSCLC
NCT06473961Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
DrugAutologous Tumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase 1
20
Shanghai
2024-10-14
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
Jialei Wang
Phase 2
60
Shanghai
2024-10-01
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
296
Shanghai
2024-09-30
Recruiting
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
NCT05613452Non-small Cell Lung Cancer
Shanghai Proton and Heavy Ion Center
Phase 2
43
Shanghai
2024-09-29
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Not yet open
Hunan Province Tumor Hospital
Phase 2
39
Changsha
2024-09-15
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
Beijing, Harbin, Shanghai
2024-09-12
Recruiting
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
NCT06596915Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Breast Cancer, Melanoma
Shandong Boan Biotechnology Co., Ltd
Phase 1
167
Beijing
2024-09-11
Not yet open
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, Ürümqi, Wenzhou
2024-09-01
Recruiting
Guangzhou Medical University
Observational
1,000
Guangzhou
2024-09-01
Recruiting
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer
Central South University
Observational
300
Changsha
2024-08-29
Recruiting
BeBetter Med Inc
Phase 2
30
Guangzhou
2024-08-28
Active, closed
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
By invitation
Shanghai Chest Hospital
Observational
500
Shanghai
2024-08-16
Active, closed
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study
NCT06461338Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Guangzhou University of Traditional Chinese Medicine
Not applicable
60
Guangzhou, Nanjing
2024-08-15
Recruiting
Beijing Chest Hospital, Capital Medical University
Phase 2
35
Beijing
2024-08-14
Recruiting
Peking Union Medical College Hospital
Phase 2
27
Beijing
2024-08-09
Recruiting
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
NCT06311981Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
Jian Chen
Phase 2
29
Shanghai
2024-08-08
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
120
Guangzhou
2024-08-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Recruiting
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2024-07-31
Recruiting
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
NCT06484816Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Shenzhen TargetRx Co., Ltd.
Phase 1
90
Hangzhou
2024-07-08
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 2
156
Nanchang
2024-07-02
Recruiting
Hunan Province Tumor Hospital
Phase 2
52
Changsha
2024-07-01
Recruiting
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
NCT06492421Lung Cancer, Surgery, Non-small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guanzhou
2024-07-01
Recruiting
The First People's Hospital of Lianyungang
Not applicable
46
Lianyungang
2024-07-01
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
64
Tianjin
2024-07-01
Recruiting
Hunan Province Tumor Hospital
Phase 2
100
Changsha
2024-07-01
Not yet open
Tang-Du Hospital
Phase 2
178
Xi'an
2024-06-30
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
570
Guangzhou
2024-06-25
Recruiting
Guangdong Provincial People's Hospital
Phase 2
25
Guangzhou
2024-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
62
Shanghai
2024-06-05
Recruiting
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
NCT06445881Non Small Cell Lung Cancer, Perioperative Complication
First Affiliated Hospital of Zhejiang University
Phase 2
60
Hangzhou
2024-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
432
Guangzhou
2024-05-22
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Recruiting
Zeng Jian
Phase 2
92
Hangzhou
2024-05-19
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
698
Beijing
2024-05-17
Recruiting
A Study of JMT203 in Patients With Cancer Cachexia
NCT06868849Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
Shanghai JMT-Bio Inc.
Phase 1/2
307
Zhejiang
2024-05-15
Recruiting
Hunan Province Tumor Hospital
Phase 2
220
Changsha
2024-05-01
Recruiting
Ji Yongling
Phase 2
20
Hangzhou
2024-05-01
Not yet open
Shouyao Holdings (Beijing) Co. LTD
Phase 3
255
Beijing
2024-05-01
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Recruiting
First People's Hospital of Hangzhou
Phase 2
40
Hangzhou
2024-04-24
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
78
Guangzhou
2024-04-24
Recruiting
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
32
Tianjin
2024-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
By invitation
Henan Cancer Hospital
Phase 2
41
Zhengzhou
2024-04-02
Recruiting
Shanghai Chest Hospital
Phase 2
54
Shanghai
2024-04-02
Active, closed
Guangdong Provincial People's Hospital
Phase 2
32
Guangzhou
2024-04-01
By invitation
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
Man Hu
Phase 1/2
100
Jinan
2024-03-30
Active, closed
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Liaoning Cancer Hospital & Institute
Observational
240
Shenyang
2024-03-21
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
506
Shanghai
2024-03-15
Recruiting
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
NCT06582940MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
Sun Yat-sen University
Phase 2
168
Guangzhou
2024-03-01
Not yet open
Myeloprotection With Trilaciclib in Pan-cancer Population
NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
DrugsTrilaciclib·Paclitaxel·Carboplatin
Sun Yat-sen University
Phase 2
132
Guangzhou
2024-03-01
Recruiting
Xin-Hua Xu
Phase 2
48
Yichang
2024-03-01
Recruiting
Sichuan University
Phase 1/2
40
Chengdu
2024-02-29
Recruiting
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
NCT06071013Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
China Medical University Hospital
Phase 1/2
20
2024-02-23
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Recruiting
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-02-08
Recruiting
Jiangsu Cancer Institute & Hospital
Observational
60
Nanjing
2024-02-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Active, closed
Ling Zhiqiang
Observational
300
Hangzhou
2024-01-01
Not yet open
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
69
Beijing
2024-01
Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
NCT06109558Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer
DrugOsimertinib
Hunan Province Tumor Hospital
Phase 1/2
120
Changsha
2023-12-31
Recruiting
Juan LI, MD
Phase 2
20
Chengdu
2023-12-31
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Recruiting
Shanghai Chest Hospital
Observational
200
Shanghai
2023-12-15
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 3
321
Guangzhou
2023-12-14
Recruiting
Jian Chen
Phase 2
77
Shanghai
2023-12-07
By invitation
Avistone Biotechnology Co., Ltd.
Phase 3
327
Guangzhou
2023-12-01
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Not yet open
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
NCT06142617Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
DrugsOsimertinib·Pemetrexed·Keytruda
Peking Union Medical College Hospital
Phase 2
37
Beijing
2023-12-01
Recruiting
3D Medicines (Sichuan) Co., Ltd.
Phase 3
390
Tianjin
2023-11-17
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Active, closed
Shouyao Holdings (Beijing) Co. LTD
Phase 3
120
Shanghai
2023-10-31
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Active, closed
Summit Therapeutics
Phase 3
1,600
Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-10-26
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
377
Shanghai
2023-10-25
Recruiting
Beijing Pearl Biotechnology Limited Liability Company
Phase 3
136
Guangzhou
2023-10-16
Recruiting
Shanghai Chest Hospital
Observational
250
Shanghai
2023-10-01
Recruiting
Shanghai Zhongshan Hospital
Phase 2
40
Shanghai
2023-09-19
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
14
Shanghai
2023-09-04
Recruiting
Ruijin Hospital
Observational
50
Shanghai
2023-08-31
Active, closed
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
Fudan University
Phase 2
202
Shanghai
2023-08-10
Recruiting
Sun Yat-sen University
Observational
150
Guanzhou
2023-08-10
Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Phase 1/2
29
Guangzhou
2023-07-26
Not yet open
Hansoh BioMedical R&D Company
Phase 1
322
Tianjin
2023-07-20
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
198
Shanghai
2023-07-19
Active, closed
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Guangzhou
2023-06-26
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Changsha, Harbin, Shanghai
2023-06-20
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
156
Shanghai
2023-06-13
Recruiting
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3
242
Shanghai
2023-05-11
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
NCT05800340Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
DrugsToripalimab·Nab-paclitaxel·Pemetrexed·Carboplatin
Guangdong Provincial People's Hospital
Phase 2
30
Guanzhou
2023-04-04
Not yet open
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-04
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Recruiting
Dizal Pharmaceuticals
Phase 2
60
Shanghai
2023-02-15
Active, closed
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 2
164
Guangzhou
2023-01-18
Active, closed
Tang-Du Hospital
Phase 2
40
Xi'an
2023-01-10
Recruiting
Integrin αvβ6-targeted PET in Malignant Tumors
NCT05835570Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic
Zhongnan Hospital
Observational
200
Wuhan
2023-01-01
Recruiting
Hunan Province Tumor Hospital
Phase 2
140
Changsha
2022-12-25
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Fuzhou, Changsha, Changchun, Hangzhou, Taizhou
2022-12-20
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-12-13
Active, closed
Pfizer
Phase 1
148
Hangzhou, Wenzhou
2022-11-30
Active, closed
Hoffmann-La Roche
Phase 3
68
Changsha, Chongqing, Jinan, Shanghai
2022-11-01
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
153
Beijing, Guangzhou, Zhengzhou
2022-10-31
Active, closed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Recruiting
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
NCT07632365Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
Shanghai Chest Hospital
Phase 1/2
108
Shanghai
2022-10-09
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Recruiting
Xinqiao Hospital of Chongqing
Observational
20
Chongqing
2022-08-01
Recruiting
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Recruiting
Henan Cancer Hospital
Phase 2
43
Zhengzhou
2022-07-26
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
DrugsKeytruda·Pembrolizumab
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Recruiting
Guangzhou University of Traditional Chinese Medicine
Not applicable
82
Guangzhou
2022-06-15
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 1
15
Tianjin
2022-05-30
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
110
Guangzhou
2022-05-20
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
80
Shijiazhuang
2022-05-01
Recruiting
Multiomics Tumor Evolution Model of NSCLC
NCT05352035Non-small Cell Lung Cancer
Peking University People's Hospital
Observational
300
Beijing
2022-04-20
Recruiting
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
NCT06706713Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
DrugBEBT-109
BeBetter Med Inc
Phase 2
200
Guangzhou, Changsha
2022-04-15
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Recruiting
Hunan Province Tumor Hospital
Phase 2
760
Changsha
2022-04-01
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Recruiting
Beijing Cancer Prevention & Treatment Society
Observational
950
Beijing
2022-01-13
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Active, closed
Li Zhang, MD
Phase 2
106
Guangzhou
2022-01-06
Active, closed
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
275
Shanghai
2021-12-31
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Recruiting
Peking Union Medical College Hospital
Phase 2
18
Beijing
2021-12-08
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Recruiting
Peking Union Medical College Hospital
Not applicable
180
Beijing
2021-11-18
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Recruiting
Hunan Province Tumor Hospital
Phase 2
90
Changsha
2021-11-13
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
27
Beijing
2021-10-25
Recruiting
Hunan Province Tumor Hospital
Observational
15,000
Changsha
2021-10-03
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
DrugMCLA-129
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Active, closed
Hutchmed
Phase 3
412
Guangzhou
2021-09-06
Active, closed
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-08-13
Active, closed
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
624
Shanghai
2021-08-11
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Haerbin, Linyi, Beijing, Shanghai
2021-08-04
By invitation
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
NCT06759857Non Small Cell Lung Cancer
DrugAfatinib
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 3
350
Beijing
2021-08-01
Recruiting
Hunan Province Tumor Hospital
Phase 2
120
Changsha
2021-08-01
Active, closed
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
The Research Plan of Taiwan Precision Medicine
NCT04849481Non-small-cell Lung Cancer
National Health Research Institutes, Taiwan
Observational
550
2021-06-23
Active, closed
Sun Yat-sen University
Observational
231
Guangzhou
2021-06-05
Recruiting
Sun Yat-sen University
Phase 3
524
Guangzhou
2021-06-01
Active, closed
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
192
Changchun
2021-04-30
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 1
198
Guangzhou
2021-04-23
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
150
Ji'nan
2021-03-18
Active, closed
Yatian Liu
Not applicable
40
Nanjing
2021-01-01
Recruiting
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
NCT06369181Neuroendocrine Carcinoma, Non-small Cell Lung Cancer, Histology Transformation
Fudan University
Observational
50
Shanghai
2021-01-01
Active, closed
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Active, closed
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
89
Shang'ai
2020-07-26
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
Nuvation Bio Inc.
Phase 2
173
Shanghai
2020-07-07
Active, closed
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Recruiting
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation
DrugsGefitinib·Brigatinib·Erlotinib·Entrectinib
Hunan Province Tumor Hospital
Phase 2
6,000
Changsha
2020-04-16
Recruiting
Hunan Province Tumor Hospital
Observational
800
Changsha
2020-03-24
Recruiting
Hunan Province Tumor Hospital
Phase 2/3
1,200
Changsha
2020-03-24
Active, closed
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Recruiting
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60,000
Beijing
2019-11-04
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Early Phase 1
11
Guangzhou
2019-09-01
Active, closed
Guangdong Association of Clinical Trials
Phase 2
316
Guangzhou
2019-08-08
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2019-07-09
Active, closed
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
Personalized DC Vaccine for Postoperative Cancer
NCT04147078Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
Sichuan University
Phase 1
80
Chengdu
2019-06-01
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Not applicable
100
Guangzhou
2018-11-01
Active, closed
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Beijing
2018-01-26
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Recruiting
Ruijin Hospital
Phase 1
15
Shanghai
2017-09-14
Recruiting
Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
NCT03392233Breast Cancer, Prostate Cancer, Non Small Cell Lung Cancer
RenJi Hospital
Phase 2
100
Shanghai
2017-08-18
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Recruiting
Shanghai Chest Hospital
Observational
250
Shanghai
2016-07-21
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangong Apt/Yuncheng, Hangzhou, Hefei
2016-05-24
Active, closed
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Rows per page Showing 1–385 of 385
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 385 of those studies listing the condition Non-small Cell Lung Cancer.

How many Non-small Cell Lung Cancer trials are recruiting in China?

240 of the 385 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 48 have not yet opened recruitment, 88 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-small Cell Lung Cancer), 385 studies
PhaseStudiesRecruitingShare
Phase 21328434.3%
Phase 3804120.8%
Observational483512.5%
Phase 1422410.9%
Phase 1/237309.6%
Not applicable30157.8%
Phase 2/31172.9%
Phase 4431%
Early Phase 1110.3%

Most active sponsors

Lead sponsors with the most studies (Non-small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.177
AstraZeneca168
Hunan Province Tumor Hospital1612
Sun Yat-sen University137
Shanghai Chest Hospital126
Merck Sharp & Dohme LLC97
Peking Union Medical College Hospital85
Shanghai Pulmonary Hospital, Shanghai, China84
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.73
Dizal Pharmaceuticals63
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.